Venclexta
E697099
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Venclexta canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7930815 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Venclexta Context triple: [AbbVie, notableProduct, Venclexta]
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Venclexta Target entity description: Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
small molecule inhibitor ⓘ targeted cancer therapy ⓘ |
| administrationRequirement |
requires dose ramp-up to reduce risk of tumor lysis syndrome
ⓘ
requires prophylaxis and monitoring for tumor lysis syndrome ⓘ |
| approvalYear | 2016 ⓘ |
| ATCCode | L01XX52 ⓘ |
| blackBoxWarning | tumor lysis syndrome ⓘ |
| chemicalStructureType | small organic molecule ⓘ |
| combinationTherapy |
used with hypomethylating agents in AML
ⓘ
used with low-dose cytarabine in AML ⓘ used with obinutuzumab in CLL ⓘ used with rituximab in CLL ⓘ |
| commonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ thrombocytopenia ⓘ |
| developer |
AbbVie
NERFINISHED
ⓘ
Genentech NERFINISHED ⓘ |
| dosageForm | tablet ⓘ |
| drugInteraction | strong CYP3A inhibitors increase venetoclax exposure ⓘ |
| hasActiveIngredient | venetoclax NERFINISHED ⓘ |
| hasBrandName | Venclyxto NERFINISHED ⓘ |
| hasDrugClass | BCL-2 inhibitor ⓘ |
| hasInternationalNonproprietaryName | venetoclax NERFINISHED ⓘ |
| hasManufacturerCountry | United States NERFINISHED ⓘ |
| indication |
acute myeloid leukemia
ⓘ
chronic lymphocytic leukemia ⓘ first-line treatment of CLL in combination regimens ⓘ relapsed or refractory CLL ⓘ small lymphocytic lymphoma NERFINISHED ⓘ |
| indicationDetail |
CLL with or without 17p deletion
ⓘ
newly diagnosed AML in adults who are 75 years or older or who have comorbidities precluding intensive induction chemotherapy ⓘ |
| legalStatus | prescription only ⓘ |
| marketedBy |
AbbVie
NERFINISHED
ⓘ
Genentech NERFINISHED ⓘ |
| mechanismOfAction |
inhibits the anti-apoptotic BCL-2 protein
ⓘ
promotes apoptosis of cancer cells ⓘ |
| metabolism | CYP3A substrate ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| regulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect | tumor lysis syndrome NERFINISHED ⓘ |
| targetsProtein | BCL-2 NERFINISHED ⓘ |
| therapeuticArea |
hematology
ⓘ
oncology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Venclexta Description of subject: Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.